Stockholders' Equity	12 Months Ended
Dec. 31, 2020
Equity [Abstract]
Stockholders' Equity	STOCKHOLDERS’ EQUITYAs of December 31, 2020 and 2019, we had losses of $8.8 million and $7.1 million, respectively, in accumulated other comprehensive loss on our Consolidated Balance Sheets. The loss as of December 31, 2020 represented the unrealized loss on our terminated interest rate swaps of $12.2 million, net of taxes, less the effective portion of the unrealized gain on our forward interest rate swap of $3.4 million, net of taxes. The loss as of December 31, 2019 represented the effective portion of the unrealized loss on our now-terminated derivative instruments. For additional information, see Note 11, Derivatives and Hedging Activities.On February 26, 2018, our board of directors authorized a $50 million stock repurchase program effective March 2, 2018 and on October 31, 2018, our board of directors approved an additional stock repurchase program, effective November 6, 2018, pursuant to which we may purchase up to an additional $100 million of our outstanding common stock. In February 28, 2020, our board of directors approved extending the current stock repurchase program to March 1, 2021. During the year ended December 31, 2020, we repurchased 633 thousand shares of our outstanding common stock with an aggregate price of approximately $33.9 million, or $53.57 average price per share. We did not repurchase any shares during the year ended December 31, 2019. As of December 31, 2020, we had $26.7 million remaining on our stock repurchase program. In response to COVID-19, we temporarily suspended our share repurchase program. Given the current state of our business and our markets, effective November 9, 2020, our share repurchase program was reinstated. The effect of these treasury shares reducing the number of common shares outstanding is reflected in our earnings per share calculation. In February, 2021, our board of directors approved extending the current stock repurchase program and increased the total amount of our outstanding common stock authorized for purchase under the program. For more details, see Note 19, Subsequent Events.

Stockholders' Equity

12 Months Ended

Dec. 31, 2020

STOCKHOLDERS’ EQUITYAs of December 31, 2020 and 2019, we had losses of $8.8 million and $7.1 million, respectively, in accumulated other comprehensive loss on our Consolidated Balance Sheets. The loss as of December 31, 2020 represented the unrealized loss on our terminated interest rate swaps of $12.2 million, net of taxes, less the effective portion of the unrealized gain on our forward interest rate swap of $3.4 million, net of taxes. The loss as of December 31, 2019 represented the effective portion of the unrealized loss on our now-terminated derivative instruments. For additional information, see Note 11, Derivatives and Hedging Activities.On February 26, 2018, our board of directors authorized a $50 million stock repurchase program effective March 2, 2018 and on October 31, 2018, our board of directors approved an additional stock repurchase program, effective November 6, 2018, pursuant to which we may purchase up to an additional $100 million of our outstanding common stock. In February 28, 2020, our board of directors approved extending the current stock repurchase program to March 1, 2021. During the year ended December 31, 2020, we repurchased 633 thousand shares of our outstanding common stock with an aggregate price of approximately $33.9 million, or $53.57 average price per share. We did not repurchase any shares during the year ended December 31, 2019. As of December 31, 2020, we had $26.7 million remaining on our stock repurchase program. In response to COVID-19, we temporarily suspended our share repurchase program. Given the current state of our business and our markets, effective November 9, 2020, our share repurchase program was reinstated. The effect of these treasury shares reducing the number of common shares outstanding is reflected in our earnings per share calculation. In February, 2021, our board of directors approved extending the current stock repurchase program and increased the total amount of our outstanding common stock authorized for purchase under the program. For more details, see Note 19, Subsequent Events.